Evaluation Using Computed Tomography Angiography (CTA) to Investigate and Detect Atherosclerotic Graft Disease (ELUCIDATE) (ELUCIDATE))
Arteriosclerosis of Coronary Artery Bypass Graft
Coronary Artery Disease
|Study Design:||Observational Model: Case-Only
Time Perspective: Retrospective
|Official Title:||Evaluation Using CTA to Investigate and Detect Atherosclerotic Graft Disease (ELUCIDATE)|
- Morphological characteristics of vein grafts [ Time Frame: two years ] [ Designated as safety issue: No ]To identify the presence of and morphological characteristics of vein graft disease in patients at 1 and 2 years post bypass surgery.
Biospecimen Retention: Samples With DNA
|Study Start Date:||December 2007|
|Estimated Study Completion Date:||June 2016|
|Estimated Primary Completion Date:||June 2016 (Final data collection date for primary outcome measure)|
Patients who have bypass surgery with using vein grafts from their legs (saphenous veins) have a very high risk of developing blockages in the grafts. It has been shown in previous studies that the progression of disease in vein grafts is very quick and can result in chest pain, heart attacks or death. In the past, evaluation of the grafts was possible with heart catheterization only. The technique of CT scan is currently considered an effective way to look at vein grafts as well as the arteries around the heart to identify blockages.
Certain blood proteins have been associated with rapid progression of vein graft blockages. Our purpose is to not only to identify blockages at different stages after bypass surgery, but to investigate the causes of the rapid progression of the disease, including clinical history, risk factors and the blood proteins.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00580008
|United States, Michigan|
|William Beaumont Hospital|
|Royal Oak, Michigan, United States, 48073|
|Principal Investigator:||Robert Safian, MD||William Beaumont Hospitals|
|Principal Investigator:||Kavitha Chinnaiyan, MD||William Beaumont Hospitals|
|Principal Investigator:||Gil Raff, MD||William Beaumont Hospitals|